^
    2d
    Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma (clinicaltrials.gov)
    P1/2, N=13, Terminated, John Kirkwood | Trial completion date: Dec 2028 --> Feb 2025 | Active, not recruiting --> Terminated; Secura Bio, Inc. discontinued support of the trial.
    Trial completion date • Trial termination
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    Opdivo (nivolumab) • Inlyta (axitinib) • Copiktra (duvelisib)
    2d
    Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer (clinicaltrials.gov)
    P2, N=62, Active, not recruiting, University of Southern California | Trial primary completion date: Dec 2025 --> Jun 2026
    Trial primary completion date • Checkpoint inhibition
    |
    PD-L1 (Programmed death ligand 1)
    |
    Inlyta (axitinib) • ivuxolimab (PF-04518600)
    8d
    Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy (clinicaltrials.gov)
    P2, N=36, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    Lenvima (lenvatinib) • Inlyta (axitinib) • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    8d
    Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC (clinicaltrials.gov)
    P2, N=75, Suspended, H. Lee Moffitt Cancer Center and Research Institute | Recruiting --> Suspended
    Trial suspension
    |
    Keytruda (pembrolizumab) • Inlyta (axitinib)
    16d
    AREN1721: A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC) (clinicaltrials.gov)
    P2, N=15, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2026 --> Nov 2026
    Trial completion date
    |
    TFE3 (Transcription Factor Binding To IGHM Enhancer 3)
    |
    Opdivo (nivolumab) • Inlyta (axitinib) • ABP 206 (nivolumab biosimilar)
    22d
    Multiple machine learning algorithms construct cuproptosis genes and oxidative stress genes-related LncRNAs signature with prognostic and therapeutic relevance in ovarian cancer. (PubMed, Genes Genomics)
    This study proposes a robust 12-lncRNA signature linking cuproptosis and oxidative stress with prognosis and therapy response in ovarian cancer, offering preliminary insights for personalized treatment guidance.
    Journal • Tumor mutational burden
    |
    TMB (Tumor Mutational Burden) • TGFB1 (Transforming Growth Factor Beta 1)
    |
    pazopanib • Inlyta (axitinib)
    23d
    FSTL1 is a prognostic marker and promotes invasion and metastasis of colon cancer. (PubMed, Discov Oncol)
    In summary, the findings of the study indicate that elevated FSTL1 expression could serve as a prognostic biomarker for unfavorable outcomes in colorectal cancer (CRC) diagnosis and may also identify potential targets for immunotherapy in CRC.
    Journal • IO biomarker
    |
    CD74 (CD74 Molecule) • FSTL1 (Follistatin Like 1)
    |
    Inlyta (axitinib)
    1m
    BL-B01D1-204-13: A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer (clinicaltrials.gov)
    P2, N=260, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | N=120 --> 260
    Enrollment change
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib) • Inlyta (axitinib) • izalontamab (SI-B001) • izalontamab brengitecan (BL-B01D1)
    1m
    A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma (clinicaltrials.gov)
    P2, N=199, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Oct 2025 --> Jul 2026 | Trial primary completion date: Oct 2025 --> Jul 2026
    Trial completion date • Trial primary completion date • Checkpoint inhibition
    |
    Keytruda (pembrolizumab) • Inlyta (axitinib) • tiragolumab (RG6058) • tobemstomig (RG6139)
    1m
    State of the art and future directions in the treatment of metastatic adenoid cystic carcinoma. (PubMed, Curr Opin Oncol)
    While conventional chemotherapy and immune checkpoint inhibitors remain largely ineffective, advances in ACC biology have driven the development of mechanism-based treatments. Future trials should prioritize biomarker-guided patient selection, rational combinations, and integration of molecular diagnostics to improve outcomes in this indolent but ultimately fatal disease.
    Journal • IO biomarker
    |
    NOTCH1 (Notch 1) • VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1)
    |
    TP53 wild-type
    |
    Lenvima (lenvatinib) • Inlyta (axitinib)
    2ms
    Mechanism of NUMBL Enhancing Axitinib Resistance in Clear Cell Renal Cell Carcinoma by UCHL1-Mediated Deubiquitination of MMP9. (PubMed, J Biol Chem)
    In our work, we investigated the mechanism by which NUMBL facilitates VM-mediated resistance at the molecular, cellular, human tissue, and animal levels. By integrating novel insights into the roles of NUMBL, VM, and deubiquitination, this research aims to establish a theoretical framework for elucidating the underlying mechanisms of axitinib resistance and provide new perspectives for improving the efficacy of axitinib in the treatment of ccRCC.
    Journal
    |
    MMP9 (Matrix metallopeptidase 9) • NUMBL (NUMB Like Endocytic Adaptor Protein)
    |
    Inlyta (axitinib)
    2ms
    Axitinib plus toripalimab as first-line treatment of clear-cell renal cell carcinoma with bone metastasis: a prospective, single-center, single-arm trial (ChiCTR2500107381)
    P=N/A, N=40, Not yet recruiting, Nanjing Drum Tower Hospital; Nanjing Drum Tower Hospital
    New trial
    |
    Loqtorzi (toripalimab-tpzi) • Inlyta (axitinib)